UK: UK's Competition Authority Sends Message, Clarifies Criteria For Ruling On Pharma Discounts

Last Updated: 23 July 2015
Article by Matt Evans

The UK's Competition and Markets Authority ("CMA") has closed an investigation under competition rules into certain discounts and rebates in the pharmaceutical sector.1 Rather than taking enforcement action or concluding that the pricing practice does not infringe UK/EU competition law, the CMA decided to close the investigation against the unnamed party because the case no longer fell within its priorities,2 but it also sent a warning letter to the company suspected of wrongdoing and issued general guidance as to the CMA's approach in assessing so-called roll-back (or retroactive) discounts and rebates under UK/EU competition law. The following key points may be noted about this case:

  • It is the first time that the CMA has issued guidance on roll-back discounts and rebates by a dominant company. The CMA's guidance does not deviate from the established UK or EU competition law position on the use of roll-back discounts and rebates but relies on economic principles previously endorsed by both the EU and U.S. antitrust agencies.
  • The fact that the CMA closed the investigation on prioritization grounds rather than on the merits, and that it issued a warning letter as well as general guidance, could suggest that the CMA is concerned that the use of potentially anticompetitive roll-back discounts and rebates may be widespread in the UK pharmaceutical industry or other sectors and that the CMA wishes to highlight what it considers to be unacceptable in the use of such pricing schemes.
  • This appears to be consistent with an emerging trend for the CMA, both in cases closed on prioritization grounds or settled by way of commitments, to issue guidance to UK businesses aimed at clarifying the law and communicating a wider deterrence message.

Background

In 2014, the CMA opened an investigation into a suspected loyalty-inducing discount scheme in the pharmaceutical sector that might have been in breach of Chapter II of the UK Competition Act 1998 and Article 102 of the Treaty on the Functioning of the EU, which both prohibit abuses of a dominant position. Neither the name of the company nor the details of the arrangements under investigation have been disclosed.

After several months of information gathering, including meetings with the company, the CMA concluded that further investigation of the conduct would have limited benefit to consumer welfare. In accordance with its own prioritization principles, the CMA issued a statement announcing the closure of its investigation without any substantive finding as to whether the conduct at issue was lawful or unlawful. However, the CMA emphasized that this did not mean that it would not look into "suspected loyalty-inducing discount schemes in the future." The CMA sent a warning letter to the company concerned and issued further guidance for pharmaceutical businesses in relation to the use of discounts and rebates.

Discounts and Rebates

Discounts and rebates in the pharmaceutical sector entail various forms of reductions in the price paid by the customer for a drug. In its statement, the CMA acknowledged that "the provision of discounts and rebates can benefit both customers—for example, through lower prices—and the business providing the discount or rebate—for example, by helping the firm achieve economies of scale and expand production". However, rebates and discounts adopted by a dominant company may sometimes violate competition rules if they have the effect of locking in customers and excluding competitors (so-called "loyalty-inducing" or "foreclosure" effects).

In the pharmaceutical sector, it is often the case that the originator of a particular drug under patent (and sometimes after patent expiration) will be found to be a dominant supplier of that drug in a national market. Discounts and rebates will rarely if ever be a problem for nondominant companies.

In the recent Intel case,3 the EU General Court distinguished three types of discounts and rebates for competition law purposes:

Quantity discounts/rebates linked to the volume of incremental purchases made from the dominant firm, which the Court generally considered lawful;

Discounts/rebates conditional on the customer purchasing "all or most" of its purchases of the relevant product from the dominant firm, which the Court considered inherently unlawful without the need to show even a capability of "loyalty-inducing" or "foreclosure" effect; and

"Other rebate systems where the grant of a financial incentive is not directly linked to a condition of exclusive or near-exclusive supply", which the court considered to be capable of being unlawful if, on a full analysis of all the circumstances, the scheme tends to exclude competitors or restrict the customer's freedom to choose his sources of supply.

The CMA's recent investigation concerned this third category of discounts/rebates, and its guidance focuses, in particular, on roll-back or retroactive discounts or rebates.

CMA Guidance

Roll-back or retroactive discounts are schemes that offer customers lower prices on units below as well as above that threshold on condition that a volume threshold is reached (also sometimes called retroactive discounts/rebates).

According to the CMA guidance, this type of scheme may be capable of inducing customer loyalty (and thus being unlawful) where the following three conditions are met:

  • There are units that a customer has no choice but to buy from the dominant company (so-called "noncontestable sales");
  • There are also units which the customer needs and which the customer may be willing and able to purchase either from the dominant company or from a competitor of the dominant company (so-called "contestable sales"); and
  • The discount or rebate scheme targets the contestable sales—the customer will be entitled to a discount or rebate if it purchases units from the dominant company that it might otherwise have chosen to buy from a competitor.

The economic theory is that dominant firms are unavoidable trading partners such that their customers will always need to purchase a certain (high) percentage of their purchasing requirements for the relevant products or services from that firm. With respect to pharmaceuticals, this scenario is more likely to surface in connection with patented drugs or drugs coming off patent, that is, when a rapid erosion of sales is anticipated due to generic entry or the entry of drugs for which customers or doctors have a therapeutic preference.

The CMA has indicated that the three conditions set out in its guidance are not exhaustive and that it is also likely to intervene where the prices (after the discount or rebate) for contestable sales are below average variable cost of production and the customer would be able to reduce its overall spending on the dominant company's products by increasing the volume of contestable sales.

The distinction between contestable and noncontestable sales and the use of average variable costs for the purpose of assessing the lawfulness of retroactive discounts and rebates are well accepted international antitrust standards, and they are relied upon by both the European Commission in its own 2009 Guidelines4 and the U.S. antitrust agencies when assessing such practices. The CMA has adopted the approach taken by the European Commission in its guidelines which requires an economic assessment to be undertaken rather than the more formalistic approach adopted by earlier EU jurisprudence. For example, in Tomra,5 the EU Court of Justice upheld an EU General Court's ruling and previous European Commission's decision that it was not necessary to calculate contestable and noncontestable sales in order to show that the retroactive rebate scheme in question was loyalty inducing and unlawful. The European Commission's Guidelines have superseded that approach, but this guidance is binding only on the European Commission itself, not also on national competition authorities (like the CMA) and courts. The fact that the CMA has explicitly said that it would apply a "contestability" test in future cases confirms that the CMA will nevertheless take the same approach as set out in the EU guidance. This is a useful indication to dominant companies in the UK that the CMA might consider the use of roll-back rebates and discounts to be permissible, provided that, on a proper economic analysis, their schemes do not make it more difficult for a competitor to compete for contestable sales.

A Warning?

On this occasion, the CMA decided to close the investigation and send a warning letter to the company under investigation and also issue general guidance for other companies. This may indicate that the CMA is concerned that the use of anticompetitive roll-back rebates or discounts is prevalent in the UK pharmaceutical or other sectors, and the CMA wishes to provide legal clarity in the expectation that businesses will assess and, if necessary, amend their current arrangements. In the future, if faced with a similar case again, it is likely the CMA then would take enforcement action. For example, in May 2015, the CMA found that an association of estate agents, three of its members and a local newspaper had breached competition rules by agreeing to restrict the advertising of fees and discounts in a local newspaper, despite the CMA's predecessor (the Office of Fair Trading) having previously warned these companies that such a practice could be anticompetitive. In that case, penalties were also imposed.

Fewer Decisions, More Guidance?

A common criticism of the CMA (and the Office of Fair Trading) is the lack of legal guidance or certainty on certain common business practices arising from the relative paucity of enforcement decisions and the resulting lack of precedents. In circumstances where the CMA seeks to manage its resources effectively by closing certain investigations on prioritization grounds rather than issuing decisions that would have precedential value, the CMA appears to be taking a two-fold approach:

  • Focusing enforcement actions on cases that involve the most serious competition law breaches, present a reasonable prospect of being successfully prosecuted and would send a strong deterrence message; and
  • Providing more guidance by way of general statements and warning letters in instances where there is a genuine concern about potentially anticompetitive practices, but not a sufficiently strong basis to bring an enforcement action either because of the lack of evidence or because of the de minimis nature of the markets concerned, or where there is just a lack of guidance or precedents.

Conclusion

The guidance provided by the CMA helpfully clarifies the economic test which the CMA will adopt in assessing under UK/EU competition rules retroactive discounts and rebates in the pharmaceutical sector. This economic approach appears to be consistent with established EU and U.S. antitrust approaches.

Although the CMA decided to close the case on prioritization grounds, it is likely that a failure to comply with this guidance by dominant companies using roll-back discounts or rebates carries a higher risk of further enforcement action by the CMA, should the arrangements come to the CMA's attention.

This case is of particular relevance for the pharmaceutical sector, although its implications go beyond the pharmaceutical sector and potentially reach out to all sectors where there is a company that is an unavoidable trading partner using retroactive discounts or rebates. Relevant businesses would therefore be well advised to assess and, if necessary, amend their current arrangements in compliance with the CMA's and other relevant EU guidance.

Footnotes

Statement regarding the CMA's decision to close an investigation into a suspected breach of competition law in the pharmaceutical sector on the grounds of administrative priority.

2  In considering whether to pursue a complaint or start an investigation ex officio, the CMA will take into account not only the merits of the matter but also whether the matter falls within its priorities, see CMA Prioritization Principles (CMA 16).

3  Case T-286/09, Intel v Commission (June 12, 2014), currently under appeal.

4  European Commission Guidance on the Commission's enforcement priorities in applying Article 82 of the EC Treaty to abusive exclusionary conduct (2009/C45/02).

5 Case C-549/10 P Tomra Systems v Commission, paragraph 79.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Matt Evans
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.